tiprankstipranks
Akari Therapeutics (AKTX)
NASDAQ:AKTX
US Market
AKTX
Akari Therapeutics
RESEARCH TOOLSreports
Want to see AKTX full AI Analyst Report?

Akari Therapeutics (AKTX) Ratios

374 Followers

Akari Therapeutics Ratios

AKTX's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, AKTX's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Mar 26Mar 25Mar 24Mar 23
Liquidity Ratios
Current Ratio
 ― 0.44 0.15 0.95 1.15
Quick Ratio
 ― 0.44 0.15 0.95 1.15
Cash Ratio
 ― 0.42 0.13 0.84 1.10
Solvency Ratio
 ― -0.88 -0.70 -2.18 -1.47
Operating Cash Flow Ratio
 ― -0.86 -0.63 -3.58 -1.79
Short-Term Operating Cash Flow Coverage
 ― -14.02 -3.85 0.00 0.00
Net Current Asset Value
$ ―$ -14.10M$ -25.38M$ -243.00K$ 1.77M
Leverage Ratios
Debt-to-Assets Ratio
 ― 0.02 0.06 0.00 0.00
Debt-to-Equity Ratio
 ― 0.03 0.15 0.00 0.00
Debt-to-Capital Ratio
 ― 0.03 0.13 0.00 0.00
Long-Term Debt-to-Capital Ratio
 ― 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 ― 1.69 2.27 -19.02 7.72
Debt Service Coverage Ratio
 ― -9.60 -6.48 0.00 0.00
Interest Coverage Ratio
 ― -18.20 88.70 0.00 0.00
Debt to Market Cap
 ― 3.10 11.19 0.00 0.00
Interest Debt Per Share
 ― 80.94 505.02 0.00 0.00
Net Debt to EBITDA
 ― 0.26 -0.03 0.23 0.57
Profitability Margins
Gross Profit Margin
―0.00%0.00%0.00%0.00%
EBIT Margin
―0.00%0.00%0.00%0.00%
EBITDA Margin
―0.00%0.00%0.00%0.00%
Operating Profit Margin
―0.00%0.00%0.00%0.00%
Pretax Profit Margin
―0.00%0.00%0.00%0.00%
Net Profit Margin
―0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin
―0.00%0.00%0.00%0.00%
Net Income Per EBT
―94.52%100.00%100.00%100.00%
EBT Per EBIT
―105.94%91.44%59.55%76.87%
Return on Assets (ROA)
―-36.12%-39.14%-229.80%-128.31%
Return on Equity (ROE)
―-61.06%-89.03%4370.31%-990.95%
Return on Capital Employed (ROCE)
―-48.61%-70.61%7338.86%-1289.11%
Return on Invested Capital (ROIC)
―-44.99%-63.82%7338.86%-1289.11%
Return on Tangible Assets
―-316.70%-670.43%-230.55%-128.47%
Earnings Yield
―-7112.00%-6790.91%-65536.80%-60481.99%
Efficiency Ratios
Receivables Turnover
 ― 0.00 0.00 0.00 0.00
Payables Turnover
 ― 0.00 0.00 0.00 0.00
Inventory Turnover
 ― 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 ― 0.00 0.00 0.00 0.00
Asset Turnover
 ― 0.00 0.00 0.00 0.00
Working Capital Turnover Ratio
 ― 0.00 0.00 0.00 0.00
Cash Conversion Cycle
 ― 0.00 0.00 0.00 0.00
Days of Sales Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Inventory Outstanding
 ― 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 ― 0.00 0.00 0.00 0.00
Operating Cycle
 ― 0.00 0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 ― -502.28 -2.10K -3.36K -6.89K
Free Cash Flow Per Share
 ― -502.28 -2.10K -3.36K -6.89K
CapEx Per Share
 ― 0.00 0.00 0.00 0.00
Free Cash Flow to Operating Cash Flow
 ― 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 ― 0.00 0.00 0.00 0.00
Capital Expenditure Coverage Ratio
 ― 0.00 0.00 0.00 0.00
Operating Cash Flow Coverage Ratio
 ― -14.02 -3.85 0.00 0.00
Operating Cash Flow to Sales Ratio
 ― 0.00 0.00 0.00 0.00
Free Cash Flow Yield
―-4344.99%-4306.98%-107603.99%-73281.76%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 ― -0.01 -0.01 >-0.01 >-0.01
Price-to-Sales (P/S) Ratio
 ― 0.00 0.00 0.00 0.00
Price-to-Book (P/B) Ratio
 ― <0.01 0.01 -0.07 0.02
Price-to-Free Cash Flow (P/FCF) Ratio
 ― -0.02 -0.02 >-0.01 >-0.01
Price-to-Operating Cash Flow Ratio
 ― -0.02 -0.02 >-0.01 >-0.01
Price-to-Earnings Growth (PEG) Ratio
 ― <0.01 <0.01 <0.01 <0.01
Price-to-Fair Value
 ― <0.01 0.01 -0.07 0.02
Enterprise Value Multiple
 ― 0.24 -0.05 0.23 0.57
Enterprise Value
 ― -4.21M 952.43K -3.83M -13.22M
EV to EBITDA
 ― 0.24 -0.05 0.23 0.57
EV to Sales
 ― 0.00 0.00 0.00 0.00
EV to Free Cash Flow
 ― 0.40 -0.08 0.23 0.61
EV to Operating Cash Flow
 ― 0.40 -0.08 0.23 0.61
Tangible Book Value Per Share
 ― -670.25 -4.25K -49.65 568.27
Shareholders’ Equity Per Share
 ― 1.35K 3.72K -46.79 573.72
Tax and Other Ratios
Effective Tax Rate
 ― 0.05 0.00 0.00 0.00
Revenue Per Share
 ― 0.00 0.00 0.00 0.00
Net Income Per Share
 ― -822.15 -3.31K -2.04K -5.69K
Tax Burden
 ― 0.95 1.00 1.00 1.00
Interest Burden
 ― 1.05 1.01 0.60 0.77
Research & Development to Revenue
 ― 0.00 0.00 0.00 0.00
SG&A to Revenue
 ― 0.00 0.00 0.00 0.00
Stock-Based Compensation to Revenue
 ― 0.00 0.00 0.00 0.00
Income Quality
 ― 0.61 0.63 1.64 1.21
Currency in USD